Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical has successfully closed its initial public offering, selling 3.2 million shares of common stock at $5.00 per share, totaling $16.0 million in gross proceeds. The IPO was facilitated by The Benchmark Company, LLC and Valuable Capital Limited as underwriters. The stock now trades on the Nasdaq Capital Market under the ticker TNON. Proceeds from the offering are expected to support Tenon's national launch of its proprietary surgical implant system for sacroiliac joint fixation, targeting a significant market opportunity.